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Running heading: 
Plaque brachytherapy for medulloepithelioma 
 
Ocular medulloepithelioma (or diktyoma) is a rare intraocular tumour of the non-pigmented 
ciliary epithelium, typically unilateral and usually in childhood. This benign or malignant 
tumour, derived from the medullary neuroepithelium of the embryonic optic cup, is non-
teratoid (containing only epithelium) or teratoid (containing neural, cartilaginous and bone 
material). Anterior chamber or orbital invasion is possible.  
 
In 1988, our group reported our experience with iridocyclectomy or enucleation as the 
primary treatment. In 16 cases, 4 underwent iridocyclectomy, but eventually all required 
enucleation.1  Other reports had similar findings.2 Recently, reports have claimed successful 
treatment with resection and adjuvant brachytherapy 3 or brachytherapy alone 4 using the 
radioisotope Iodine-125. We evaluated our recent series of cases treated with Ruthenium-
106 plaque brachytherapy in the primary management of medulloepithelioma. 
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A retrospective medical record review was performed of consecutive patients with 
medulloepithelioma at the paediatric ocular oncology service at Moorfields Eye Hospital and 
the Royal London Hospital (Clinical Effectiveness Unit of Barts Health NHS Trust number 
5398). There were 6 patients (4 male) diagnosed with medulloepithelioma between January 
2005 and December 2012. The mean (median, range) age of presentation was 58 (55, 9 – 
141) months. The referring diagnosis, medical history and clinical features (Figure 1) are 
detailed in Table 1 (available at http://aaojournal.org). All patients presented with a mass or 
cystic lesion, with involvement of 4 (4, 2 – 9) clock hours. The B scan height was 4.0 (3.6, 3 
– 5.9) mm. Lens notch was present 50%, sectoral cataract in 33%, and anterior synechiae 
in17%. Intraocular pressures were normal. Retrolental thickened cyclictic membrane was 
absent. 5 
 
The diagnosis was known in only Patient 6, after vitreolensectomy and fine needle aspiration 
biopsy elsewhere. Due to a rapidly enlarging mass, scleral thinning, iris neovascularisation, 
ectropion uveae and vitreous seeds this eye was enucleated. The histopathology findings 
were of a tumour composed of ribbons of pseudostratified cells, with numerous mitoses. 
There were areas of necrosis with undifferentiated sheets of cells, with occasional rosette 
formation. There was a focus of choroidal and early scleral invasion, so adjuvant systemic 
chemotherapy was given and the child remains metastasis free. 
 
Plaque brachytherapy was performed in the remaining 5 eyes (by JLH or MSS) with 12 mm 
circular ruthenium-106 applicators (Bebig, Germany), delivering a tumour apex radiation 
dose of 40 – 50 Gy. All tumours reduced in height, and change in B scan tumour height was 
-1.0 (-1.0, -0.2 – -1.4) mm. Regression (>0.5mm in reduction in B scan height) occurred in 4 
out of 5 eyes (80%). In 1 tumour the reduction in height was 0.2 mm, deemed stable. During 
follow-up of 26 (14, 9-57) months, there were no cases of tumour relapse, corneal oedema, 
raised intraocular pressure, progression of cataract, secondary enucleation or regional or 
distant metastasis. Iris neovascularisation was seen in 1 eye at 11 months after plaque 
brachytherapy, while non-proliferative retinopathy was diagnosed in another eye at 12 
months. Visual acuity (Table 2 available at http://aaojournal.org) remained stable or 
improved in 4 out of 5 eyes (80%) and in 1 case amblyopia had developed before diagnosis, 
with no response to patching the better eye.  
 
Our series of 6 cases managed over 7 years, concurs with two other international centres 
that treated 31 cases over 42 years and 10 cases in 12 years respectively.5 Initial 
misdiagnosis, unnecessary surgical procedures and delayed referral occur frequently.2, 5 
Similarly, in the current series only one patient was referred with the correct diagnosis. The 
majority of cases in the literature have been treated with enucleation.1, 5 Partial lamellar 
sclerouvectomy (PLSU) or iridocyclectomy is a treatment option for circumscribed lesions, 
but it carries a high rate of recurrence.1, 2 Cryotherapy has been reserved in some cases for 
small lesions or minor local recurrences.2  
 
The use of radiotherapy in medulloepithelioma has been evaluated before. External beam 
radiotherapy was to salvage eyes after surgical resection or as adjuvant therapy in eyes with 
extrascleral or orbital extension.1  The use of plaque brachytherapy has received sparse 
attention in the literature. Two reports described its use as an adjuvant therapy after PLSU in 
three patients.2, 3  Only in one such instance was it possible to avoid subsequent 
enucleation.3 Another case report described the situation where the medulloepithelioma 
responded to iodine-125 brachytherapy, avoiding planned PLSU.4 The role and safety of 
ruthenium-106 plaque brachytherapy alone has not yet been reported. The idea of using this 
β-radiation emitting isotope is an attractive one, since its complication profile is less than that 
of the x ray and γ-emitting iodine-125 or of charged particles.  In a recent report of 41 cases, 
plaque brachytherapy was used as a primary treatment in 3 eyes with medulloepithelioma 
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with good tumour control.5 However, the radioisotope used was not stated. As in other 
reports, we chose a radiation dose of 40-50Gy.4, 5 Previously Cassoux and colleagues gave 
a dose of 25Gy to the tumour apex but applied this dose twice.3  Our larger height tumours 
were given 50Gy to the apex, to ensure sufficient coverage of the tumour.  
 
In the current series all brachytherapy treated tumours had a height under 5mm, and 80% 
regressed. During 26 months follow-up, none of the eyes required enucleation or relapsed. 
These cases were less advanced without diffuse retrolental cyclitic membranes, which may 
explain our rate of tumour control. As the tumours were small, the change in height is also 
small. A biopsy was not performed, so it is impossible to comment on the presence of 
malignant cells. However, the rationale for brachytherapy is to neutralise any malignant 
components. It is likely that this has been achieved, as there were no cases of local or 
systemic relapse. With longer follow-up there is a possibility of recurrence or complications, 
such as cataract progression or neovascularisation that require further intervention.  
 
Our results suggest that Ruthenium-106 plaque brachytherapy achieved excellent tumour 
control, avoiding enucleation and sparing vision. The long-term implications of plaque 
brachytherapy are currently unknown, but as metastasis is relatively uncommon, we believe 
that plaque brachytherapy coupled with careful surveillance is appropriate in the initial 
management of a small-localised medulloepithelioma. 
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Figure legend 
Fig 1: Characteristic findings in Medulloepithelioma. 
A. Colour photograph showing lens notch with lesion attached to the lens and B. showing 
clump of cysts on the ciliary body C.  Large clump of cysts with underlying white mass – this 
eye was enucleated due to extensive disease at presentation D. Anterior segment view of 
medulloepithelioma eroding through the iris. E. Example of pre-treatment B ultrasound scan 
image F. B ultrasound scan image of the same patient as E, following plaque radiotherapy. 
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Table 1: Plaque brachytherapy for medulloepithelioma: Clinical Features 
Feature 
          
No (%) 
N=6 
Referring diagnosis      
 Mass lesion     1 (17) 
 Ciliary body cyst     2 (33) 
 Medulloepithelioma    1 (17) 
 Glaucoma     1 (17) 
 Inflammatory eye disease    1 (17) 
Past medical history      
 None      5 (83) 
 
CHARGE 
syndrome     1 (17) 
Previous ocular history      
 None      2 (33) 
 Trauma      1 (17) 
 Vitreolensectomy     1 (17) 
 Sectorial cataract     1 (17) 
 Amblyopia   1 (17) 
 Coloboma of CHARGE syndrome   1 (17) 
 
Clinical 
findings at 
presentation            
Colour of lesion       
 White      3 (50) 
 Grey      3 (50) 
Tumour appearance      
 Ciliary body mass with grape like cystic lesions  5 (83) 
 
Corrugated lesion with cystic changes and overlying 
pigment   1 (17) 
Associated features      
 Lens notch     3 (50) 
 Sector cataract     2 (33) 
 Iris coloboma     1 (17) 
 Anterior synechiae     1 (17) 
 
Ectropion uveae with iris 
neovascularisation    1 (17) 
Quadrants invovled      
 Superotemporal     2 (33) 
 Inferotemporal     2 (33) 
 Inferonasal     1 (17) 
 Inferotemporal and superotemporal   1 (17) 
 
CHARGE syndrome: coloboma of the eye; heart anomaly; choanal atresia; retardation of 
mental and somatic development; genital/urinary abnormalities; ear abnormalities and/or 
deafness. 
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Table 2: Visual acuity results before and after Ru-106 plaque brachytherapy for 
medulloepithelioma. 
Visual Acuity outcomes 
 
  
Patient VA before 
treatment 
Age 
(months) 
Method 
used 
VA after 
treatment 
Age 
(months) 
Method used 
1 6/24 60 Snellen 6/19 71 Snellen 
2 6/19 36 Cardiff 
cards 
6/7 51 Snellen 
3 6/75 9 Keeler 6/19 16 Cardiff cards 
4 6/12 9 Cardiff 
cards 
6/7.6 51 Kay pictures 
5 6/24 132 Snellen 6/38 137 Snellen 
6 Perception of 
light 
60  N/A 92 Enucleated 
 
VA – visual acuity 
 
 
 
 
 
 
 
 
 
 
